Combined Metabolic Activators Improve Brain and Liver Function in Alzheimer's and Parkinson's Disease: Preclinical Findings

Synopsis

Mitochondrial dysfunction and metabolic problems are major contributors to neurodegenerative diseases such as Parkinson’s (PD) and Alzheimer’s (AD). Research shows that combined metabolic activators (CMAs)—including glutathione precursors (L-serine and N-acetyl cysteine), the NAD+ precursor nicotinamide riboside, and L-carnitine tartrate—can improve these issues and support mitochondrial function, potentially slowing disease progression. Two CMA formulations—CMA1 (nicotinamide riboside, L-serine, N-acetyl cysteine, L-carnitine tartrate) and CMA2 (nicotinamide, L-serine, N-acetyl cysteine, L-carnitine tartrate)—were tested in animal models of AD and PD, with assessments of brain and liver tissues, as well as behavioral responses in PD models. Both CMAs reduced brain cell damage and improved liver metabolism, with CMA2 showing stronger effects, including better behavioral outcomes in PD rats. These findings suggest that CMA1 and CMA2 enhance metabolic and cognitive function, with CMA2 showing particular promise as a therapy for AD and PD.

Journal

Biomedicines